SL65.0155 is a selective 5-HT4 receptor partial agonist (Ki = 0.6 nM; IA = 40-50% (relative to 5-HT)). It potently enhances cognition learning and memory and also possesses antidepressant effects. SL65.0155 was in phase II clinical trials around 2004-2006 for the treatment of memory deficits and dementia but no new information has surfaced since and it appears to have been abandoned.
This page contains content from the copyrighted Wikipedia article "SL65.0155"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
